Psychiatr. pro Praxi, 2009; 10(4): 167-170

Rational and nonrational use of antipsychotics in gerontopsychiatry

doc. MUDr. Roman Jirák CSc
Psychiatrická klinika 1. LF UK a VFN Praha

In gerontopsychiatry, states of agitation or other disorders requiring sedation are often encountered. They are most commonly behaviour

disorders in dementias, deliria, and psychotic conditions at older age (sometimes associated with the dementia syndrome, sometimes not).

There is a general trend to calm such states as soon as possible. First, attempts are made to ease agitation or other unwanted behaviour

disorders with nonpharmacological methods, but these efforts are not always successful. Therefore, antipsychotics are used at a large

scale. Their use often is nonrational resulting in their overuse. At times, their use is necessary since severe agitation, delirium, or psychotic

symptoms may be life-threatening to patients. Antipsychotics with minimal adverse effects should be used. For that reason, first-generation

antipsychotics are not routinely used. There are exceptions – melperone, whose properties are close to those of the second-generation

antipsychotics, is normally used, and, in severe agitation, haloperidol is used in a single dose or in a short term. For deliria and agitation in

dementia, tiapride is widely used; however, its antipsychotic potential is low. When psychotic symptoms are predominant, other atypical

antipsychotics are used. Their benefits and risks are discussed. In behaviour disorders associated with dementia, the use of acetylcholinesterase

inhibitors and memantine is appropriate.

Keywords: antipsychotics, delirium, dementia, agitation, behaviour disorders.

Published: August 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirák R. Rational and nonrational use of antipsychotics in gerontopsychiatry. Psychiatr. praxi. 2009;10(4):167-170.
Download citation

References

  1. Katona C. Psychotropics and drug interactions in the elderly patients. Int J Geriatr Psychiatry 2001; 16: S86-S90. Go to original source...
  2. Květina J. Gerontofarmakologie. In: Kalvach Z, Zadák Z, Jirák R, Zavázalová H, Sucharda P. (eds.) a kol. Geriatrie a gerontologie. Praha: Grada, 2004: 365-375 s.
  3. Jirák R, Borzová C, Konrád J, Franková V, Spousta S. Demence. In: Raboch J, Anders M, Praško J, Hellerová P. (eds.) a kol. Psychiatrie. Doporučené postupy psychiatrické péče 2. Infopharm, Praha, 2006: 22-37 s.
  4. Jirák R, Franková V. Demence a jiné organicky podmíněné poruchy. In: Seifertová D, Praško J, Horáček J, Höschl C. (eds) a kol. Postupy v léčbě psychických poruch. Algoritmy České neuropsychofarmakologické společnosti. Medical Tribune CZ, Praha, 2008: 12-29 s.
  5. Verma S, Orengo CA, Kunik ME, Hale D, Molinari VA. Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients. Int. J. Geriatr. Psychiatry 2001; 16: 223-227. Go to original source...
  6. Wood-Mitchell A, James IA, Waterworth A, et al. Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia; a qualitative study. Age and Ageing 2008; 37(5): 547-552. Go to original source... Go to PubMed...
  7. Hermann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005; 19: 91-103. Go to original source... Go to PubMed...
  8. Wooltorton E. Risperidone (Risperdal): Increased rate of cerebrovascular events in dementia trials. CMAJ 2004; 167(11): 1269-1270. Go to original source... Go to PubMed...
  9. Nasrallah HA, White T, Nasrallah A. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. Am J Geriatr Psychiatry 2004; 12(4): 437-439. Go to original source...
  10. Wooltotron E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ, 2004; 27, 170(9).doi: 10.1503/cmaj.1040539. Go to original source... Go to PubMed...
  11. Ciudad A, Montes JM, Olivares JM, et al. Safety and tolerability of olanzapine compared with antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study. Eropean Psychiatry 2005; 19: 358-365. Go to original source...
  12. Barak Y, Shamir E, Mirecki I, Weizman R and Aizenberg D. Switching elderly chronic psychotic patiens to olanzapine. International Journal of Neuropsychopharmacology 2004; 7: 165-169. Go to original source... Go to PubMed...
  13. Hwang JP, Yang ChH, Lee TW, Tsai SJ. The efficacy and safety of olanzapine for the treatment of geriatric psychosis. J Clin Psychopharmacol 2003; 23: 113-118. Go to original source... Go to PubMed...
  14. Ritchie CW, Chiu E, Harrigan S, et al. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patiens with schizophrenia: an open study of six months durativ. Int J Geriatr Psychiatry 2006; 21: 171-179. Go to original source... Go to PubMed...
  15. Feldman PD, Kaiser ChJ, Kennedy JS, et al. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. J Clin Psychiatry 2003; 64: 998-1004. Go to original source... Go to PubMed...
  16. Kennedy JS, Jeste D, Kaiser CJ, et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatry 2003; 18: 1013-1020. Go to original source... Go to PubMed...
  17. Sajatovic M, Subramoniam Madhusoodanan S, Coconcea N. Managing Bipolar Disorder in the Elderly. Defining the Role of the Newer Agents. Drugs Aging 2005; 22(1): 39-54. Go to original source... Go to PubMed...
  18. Praško J, Jirák R, Franková V, Seifertová D. Delirium. In: Seifertová D, Praško J, Horáček J, Höschl C (eds.) a kol. Postupy v léčbě psychických poruch. Algoritmy České neuropsychofarmakologické společnosti. Medical Tribune CZ, Praha, 2008: 29-39 s.
  19. Rochon PA, Normand SL, Gomes T. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008; 168(10): 1090-1096. Go to original source... Go to PubMed...
  20. Jirák R, Koukolík F. Demence. Neurobiologie, klinický obraz, terapie. Praha: Galén 2004; 255-257.
  21. Caltagirone C, Bianchetti A, Di Luca M, et al. Guidelines for the treatment of Alzheimer´s disease from the Italian Association of Psychogeriatrics. Drugs & Aging 2005; 22(Suppl. 1): 1-26. Go to original source... Go to PubMed...
  22. Lonergan E, Luxenberg J, Colford JM, Birks J. Haloperidol for agitation in dementia. Cochrane Database of Systemnatic Reviews 2002, Issue 2. Last assessed as up-to-date: Sept. 12. 2008. Go to original source...
  23. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Metaanalysis of randomized Placebo-controlled trials. JAMA, 2005; 19, 294(15): 1934-1943. Go to original source... Go to PubMed...
  24. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer´s disease. N Engl J Med 2006; 12, 355(15): 1525-1538. Go to original source... Go to PubMed...
  25. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer disease in nursing care facilities. Archives of General Psychiatry 2000; 57: 968-976. Go to original source... Go to PubMed...
  26. Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medication in Alzheimer´s disease: Phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165: 844-854. Go to original source... Go to PubMed...
  27. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64(2): 134-143. Go to original source... Go to PubMed...
  28. Zhong KX, Tariot PN, Mintzer J, et al. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebocontrolled study. Curr Alzheimer Res. 2007; 4(1): 81-93. Go to original source... Go to PubMed...
  29. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioral symptoms in Alzheimer´s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomized, controlled studies. Int J Geriatr Psychiatry 2005; 20(5): 459-464. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.